Fertility drugs and young-onset breast cancer: Results from the two sister study

Journal of the National Cancer Institute

Volumn 104, Issue 13, 2012, Pages 1021-1027

  Fei, Chunyuan ^a   Deroo, Lisa A ^a   Sandler, Dale P ^a   Weinberg, Clarice R ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE CITRATE; ESTROGEN RECEPTOR; FERTILITY PROMOTING AGENT; FOLLITROPIN; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; ONSET AGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGE OF ONSET; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CLOMIPHENE; ESTROGEN ANTAGONISTS; FEMALE; FERTILITY AGENTS; FOLLICLE STIMULATING HORMONE; HUMANS; LOGISTIC MODELS; ODDS RATIO; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; RECEPTORS, ESTROGEN; RISK ASSESSMENT; RISK FACTORS; SIBLINGS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863910444     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs255     Document Type: Article

References (38)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
2. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev. 1993;15(1):36-47.
3. Wu HH, Wang NM, Cheng ML, Hsieh JN. A randomized comparison of ovulation induction and hormone profile between the aromatase inhibitor anastrozole and clomiphene citrate in women with infertility. Gynecol Endocrinol. 2007;23(2):76-81.
4. Badawy A, Elnashar A, Totongy M. Clomiphene citrate or aromatase inhibitors for superovulation in women with unexplained infertility undergoing intrauterine insemination: a prospective randomized trial. Fertil Steril. 2009;92(4):1355-1359.
5. Barrenetxea G, Agirregoikoa JA, Jimenez MR, de Larruzea AL, Ganzabal T, Carbonero K. Ovarian response and pregnancy outcome in poorresponder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertil Steril. 2008;89(3):546-553.
6. Lass A. Monitoring of in vitro fertilization-embryo transfer cycles by ultrasound versus by ultrasound and hormonal levels: a prospective, multicenter, randomized study. Fertil Steril. 2003;80(1):80-85.
7. Dickey RP, Hower JF. Effect of ovulation induction on uterine blood flow and oestradiol and progesterone concentrations in early pregnancy. Hum Reprod. 1995;10(11):2875-2879.
8. Hassiakos D, Mantzavinos T, Kalomiris K, Zourlas PA. Comparison of maternal serum estradiol and progesterone levels in pregnancies after induced and spontaneous ovulation. Arch Gynecol Obstet. 1991;248(3):145-150.
9. Schieve LA, Devine O, Boyle CA, Petrini JR, Warner L. Estimation of the contribution of non-assisted reproductive technology ovulation stimulation fertility treatments to US singleton and multiple births. Am J Epidemiol. 2009;170(11):1396-1407.
10. Ricci E, Parazzini F, Negri E, Marsico S, La Vecchia C. Fertility drugs and the risk of breast cancer. Hum Reprod. 1999;14(6):1653-1655.
11. Calderon-Margalit R, Friedlander Y, Yanetz R, et al. Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol. 2009;169(3):365-375.
12. Braga C, Negri E, La Vecchia C, Parazzini F, Dal Maso L, Franceschi S. Fertility treatment and risk of breast cancer. Hum Reprod. 1996;11(2):300-303.
13. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet. 1999;354(9190):1586- 1590.
14. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet. 1995;346(8981):995-1000.
15. Terry KL, Willett WC, Rich-Edwards JW, Michels KB. A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. Arch Intern Med. 2006;166(22):2484-2489.
16. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Risk of breast cancer in a cohort of infertile women. Gynecol Oncol. 1996;60(1):3-7.
17. Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A. Fertility drugs and the risk of breast and ovarian cancers: results of a longterm follow-up study. Fertil Steril. 1999;71(5):853-859.
18. Pappo I, Lerner-Geva L, Halevy A, et al. The possible association between IVF and breast cancer incidence. Ann Surg Oncol. 2008;15(4):1048-1055.
19. Orgeas CC, Sanner K, Hall P, et al. Breast cancer incidence after hormonal infertility treatment in Sweden: a cohort study. Am J Obstet Gynecol. 2009;200(1):72.e1-72.e7.
20. Modan B, Ron E, Lerner-Geva L, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol. 1998;147(11):1038-1042.
21. Lerner-Geva L, Keinan-Boker L, Blumstein T, et al. Infertility, ovulation induction treatments and the incidence of breast cancer - A historical prospective cohort of Israeli women. Breast Cancer Res Treat. 2006;100(2):201-212.
22. Lerner-Geva L, Geva E, Lessing JB, Chetrit A, Modan B, Amit A. The possible association between in vitro fertilization treatments and cancer development. Int J Gynecol Cancer. 2003;13(1):23-27.
23. Kristiansson P, Bjor O, Wramsby H. Tumour incidence in Swedish women who gave birth following IVF treatment. Hum Reprod. 2007;22(2):421-426.
24. Kotsopoulos J, Librach CL, Lubinski J, et al. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control. 2008;19(10):1111-1119.
25. Kallen B, Finnstrom O, Lindam A, Nilsson E, Nygren KG, Olausson PO. Malignancies among women who gave birth after in vitro fertilization. Hum Reprod. 2011;26(1):253-258.
26. Jensen A, Sharif H, Svare EI, Frederiksen K, Kjaer SK. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16(7):1400-1407.
27. Gauthier E, Paoletti X, Clavel-Chapelon F, E3N Group. Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study. Hum Reprod. 2004;19(10):2216-2221.
28. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod. 2002;17(8):2209-2213.
29. Dor J, Lerner-Geva L, Rabinovici J, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril. 2002;77(2):324-327.
30. Burkman RT, Tang MT, Malone KE, et al. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study. Fertil Steril. 2003;79(4):844-851.
31. Brinton LA, Scoccia B, Moghissi KS, et al. Breast cancer risk associated with ovulation-stimulating drugs. Hum Reprod. 2004;19(9):2005-2013.
32. Zreik TG, Mazloom A, Chen Y, et al. Fertility drugs and the risk of breast cancer: a meta-analysis and review. Breast Cancer Res Treat. 2010;124(1):13-26.
33. Axelrod D, Smith J, Kornreich D, et al. Breast cancer in young women. J Am Coll Surg. 2008;206(3):1193-1203.
34. Kelley KE, Kelley TP, Kaufman DW, Mitchell AA. The Slone Drug Dictionary: a research driven pharmacoepidemiology tool. Pharmacoepidemiol Drug Saf. 2003;12(suppl 1):S168-S169.
35. Glymour M, Greenland S. Causal diagrams. In: Rothman K, Greenland S, Lash T, eds. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:183-209.
36. Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv. 2008;63(3):163-181.
37. Polyak K. Pregnancy and breast cancer: the other side of the coin. Cancer Cell. 2006;9(3):151-153.
38. Homburg R. Clomiphene citrate-end of an era? A mini-review. Hum Reprod. 2005;20(8):2043-2051.